

This is the English translation of a Japanese press release published on February 13, 2026. If there are any differences in content or interpretation, the Japanese version shall prevail.

February 13, 2026

<p style="text-align: center;">Notice Regarding Setting of Record Date for Convening Extraordinary General Meeting of Shareholders</p>

Hisamitsu Pharmaceutical Co., Inc. (the “Company”) hereby announces that, pursuant to a resolution adopted at a meeting of the Board of Directors held today, the Company has decided to set a record date for the purpose of convening an extraordinary general meeting of shareholders scheduled to be held around mid-April 2026 (the “Extraordinary General Meeting of Shareholders”), as set forth below.

1. Record Date for the Extraordinary General Meeting of Shareholders

In order to determine the shareholders entitled to exercise their voting rights at the Extraordinary General Meeting of Shareholders, the Company has designated February 28, 2026 (Saturday) (which is a holiday, and therefore, in practice, February 27, 2026 (Friday)) as the record date, and shareholders who are recorded or registered in the final shareholders’ registry as of such record date shall be entitled to exercise their voting rights at the Extraordinary General Meeting of Shareholders. The public notice of the record date will be made as follows:

- | | |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (i) Record date | February 28, 2026 (Saturday) |
| (ii) Date of public notice | February 13, 2026 (Friday) |
| (iii) Method of public notice | Public notice by electronic means
(to be posted on the following website of the Company.)
https://www.hisamitsu.co.jp/ir/koukoku.html |

2. Schedule of the Extraordinary General Meeting of Shareholders and Matters to Be Submitted

As announced in the Company’s press release entitled “Announcement of Implementation of MBO and Recommendation for Tendering Shares” dated January 6, 2026, TAIYO KOSAN CO., INC. (the “Offeror”) has stated that, in the tender offer for the Company’s common stock (the “Company’s Stock”), the Share Acquisition Rights (Note 1) and the American Depositary Receipts (Note 2) (the “Tender Offer”), if the Offeror is unable to acquire all of the Company’s Stock (including any Company’s Stock deliverable upon exercise of the share acquisition rights, but excluding treasury shares held by the Company and the Non-tendered Shares (Note 3)), the Share Acquisition Rights and the American Depositary Receipts through the Tender Offer, the Offeror plans, following the completion of the Tender Offer, to implement a series of procedures to make the Offeror and the Non-tendering Shareholders (Note 3) the only shareholders of the Company.

Specifically, the Offeror plans to request the Company, promptly after the completion of the settlement of the Tender Offer, to convene an extraordinary general meeting of shareholders to submit proposals including (i) the consolidation of the Company’s Stock pursuant to Article 180 of the

Companies Act of Japan (Act No. 86 of 2005, as amended; the “Companies Act”) (the “Share Consolidation”), and (ii) a partial amendment to the Company’s articles of incorporation to abolish the provisions regarding the number of shares constituting one unit, subject to the effectiveness of the Share Consolidation (the “Request”). The Offeror plans to vote in favor of each of such proposals at the Extraordinary General Meeting of Shareholders.

In preparation for the possible convening of the Extraordinary General Meeting of Shareholders in response to the Request, the Company has decided to set, in advance, the record date necessary for convening the Extraordinary General Meeting of Shareholders, as described in “1. Record Date for the Extraordinary General Meeting of Shareholders” above. The date, venue and details of the agenda items of the Extraordinary General Meeting of Shareholders will be announced once they are determined.

On the other hand, if (i) the Tender Offer is not completed, or (ii) the Tender Offer is completed and the Offeror successfully acquires all of the Company’s Stock (including any Company’s Stock deliverable upon exercise of the Share Acquisition Rights, but excluding treasury shares held by the Company and the Non-tendered Shares) through the Tender Offer, the Company does not plan to convene the Extraordinary General Meeting of Shareholders, and the above-mentioned record date will not be used.

(Note 1)

The term “Share Acquisition Rights” collectively refers to the following share acquisition rights:

- (i) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 10, 2015 (exercise period: July 28, 2015 to July 27, 2065)
- (ii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 8, 2016 (exercise period: July 26, 2016 to July 25, 2066)
- (iii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 7, 2017 (exercise period: July 26, 2017 to July 25, 2067)
- (iv) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 6, 2018 (exercise period: July 25, 2018 to July 24, 2068)
- (v) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 10, 2019 (exercise period: July 27, 2019 to July 26, 2069)
- (vi) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 9, 2020 (exercise period: July 29, 2020 to July 28, 2070)
- (vii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 8, 2021 (exercise period: July 27, 2021 to July 26, 2071)
- (viii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 7, 2022 (exercise period: July 26, 2022 to July 25, 2072)
- (ix) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 13, 2023 (exercise period: August 1, 2023 to July 31, 2073)
- (x) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s Board of Directors held on July 11, 2024 (exercise period: July 30, 2024 to July 29, 2074)
- (xi) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s

Board of Directors held on July 10, 2025 (exercise period: July 29, 2025 to July 28, 2075)

(Note 2)

The term “American Depositary Receipts” refers to the American Depositary Receipts representing the Company’s common stock issued in the United States by Citibank, N.A.

(Note 3)

The term “Non-tendered Shares” refers to an aggregate of 4,044,142 shares, consisting of (i) an aggregate of 3,917,742 Company’s Stock held by Mr. Kazuhide Nakatomi, TKY CO., INC., Nakatomi Asset Management Co., Inc., SSTM CO., INC., STM CO., INC., and TM CO., LTD., and (ii) 126,400 Company’s Stock held by Nakatomi Kosan Co., Inc. (Mr. Kazuhide Nakatomi, TKY CO., INC., Nakatomi Asset Management Co., Inc., SSTM CO., INC., STM CO., INC., TM CO., LTD., and Nakatomi Kosan Co., Inc. are hereinafter collectively referred to as the “Non-tendering Shareholders”).